GSK’s (GSK) niraparib was granted FDA orphan designation as a treatment of malignant glioma, according to a post to the agency’s website.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- ViiV Healthcare announces 96-week data from PASO DOBLE on Dovato
- GSK’s Asthma Study Update: Potential Market Impacts
- Midday Fly By: Salesforce targets $60B in revenue, TSMC reports Q3 beat
- GSK CEO downplays role in leucovorin FDA effort, STAT reports
- GSK’s RSV Vaccine Study Update: Promising Developments for Older Adults